Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/1/2026, 12:00:00 AM
The U.S. FDA accepted for Priority Review the sNDA for Camzyos on 2026-06-01. This regulatory milestone is estimated to have a >1% price impact expected.
Korean Translation
2026년 6월 1일, 미국 FDA가 캠지오스의 보충 신약 허가 신청을 우선 심사 대상으로 접수함. 규제 승인 기대감으로 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release is scheduled. This event is estimated to have a price impact of at least 1%.
8/6/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife is scheduled to release its Q2 2026 earnings results on August 5, 2026; a medium impact is expected as quarterly results are key performance indicators, scheduled.
8/5/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release scheduled. Analysts forecast an EPS of approximately $1.63 to $1.66 forecasted. Low importance estimated: historical price reaction to earnings is typically 1-5%.
8/3/2026, 12:00:00 AM
The Cigna Group (CI) · Earnings Release
Second quarter 2026 financial results are scheduled to be released. This recurring financial event is estimated to have a medium price impact of at least 5% based on historical volatility scheduled.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM